All In Biotech

Drug Trial Radar · NCT06540144

An Extension Study Evaluating 6-week Treatment Cycles of Rozanolixizumab in Pediatric Study Participants With Generalized Myasthenia Gravis

An Open-label Extension Study to Evaluate Rozanolixizumab in Pediatric Study Participants With Generalized Myasthenia Gravis

Last checked: Nov 20, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

13

Actual

Start

Oct 8, 2024

Primary completion

Oct 5, 2027

Study completion Oct 5, 2027

Sponsor

Lead sponsor
UCB Biopharma SRLUCB
Sponsor type
Industry
First posted
Aug 6, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 2 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to assess the long term safety and tolerability of additional 6-week treatment cycles with rozanolixizumab in pediatric participants with generalized Myasthenia Gravis (gMG) aged ≥2 at the time of the Screening Visit of MG0006.

Conditions

  • Generalized Myasthenia Gravis

Interventions

  • rozanolixizumabDrug

    rozanolixizumab solution for injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Occurrence of serious Treatment-Emergent Adverse Events (TEAEs) up to the End of Study (EOS) VisitTime frame: From Baseline up to the EOS Visit (up to 52 weeks)
  2. Occurrence of TEAEs leading to permanent withdrawal of IMP up to the EOS VisitTime frame: From Baseline up to the EOS Visit (up to 52 weeks)
  3. Occurrence of Adverse Event(s) of Special Monitoring (AESM) up to the EOS VisitTime frame: From Baseline up to the EOS Visit (up to 52 weeks)

Locations

9 sites in 4 countries. Site status is shown where the registry gives one.

  • Mg0008 40290

    Bologna, Italy

  • Mg0008 40144

    Milan, Italy

  • Mg0008 40733

    Naples, Italy

  • Mg0008 20340

    Fuchu-shi, Japan

  • Mg0008 20339

    Ōbu, Japan

  • Mg0008 20343

    Sagamihara, Japan

  • Mg0008 40734

    Lodz, Poland

  • Mg0008 40155

    Warsaw, Poland

  • Mg0008 40841

    Yenimahalle, Turkey (Türkiye)

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.